Biogen Ma Inc.

Nathan Genung

Kevin Guckian

Jeffrey Vessels

Zhili Xin

Lei Zhang

Edward Yin Shiang Lin

Ryan Gianatassio

Joseph P Lyssikatos

Gnanasambandam Kumaravel

Jermaine Thomas

Brian Stuart Lucas

Tracy J Jenkins

Timothy Raymond Chan

Robert Meissner

Irina Leaf

Jeremy Duffield

Kevin M Guckian

Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, and Z are as defined herein.

Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, m, n, and p are as defined herein.

Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R, R, R, Y, Y, Ar, Z and n are as defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I&#x2033;) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, R, R, m, n, Y, Y, Rand Rare defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

Growing community of inventors

Cambridge, MA, United States of America

Nathan Genung